Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2020 Earnings Presentation
9 slides from Anika Therapeutics's earnings presentation, Nov 4, 2020
Slide 1: Third Quarter 2020 Earnings Call Presentation
THIRD QUARTER 2020 EARNINGS CALL PRESENTATION NOVEMBER 4, 2020
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Who We Are
WHO WE ARE • A global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care • Committed to leading in high opportunity spaces within orthopedics • Partner with physicians to understand what they need most to treat their patients • Develop
Slide 4: Executing on All Elements of Growth Strategy
EXECUTING ON ALL ELEMENTS OF GROWTH STRATEGY • Grew total revenue by 7% year-over-year in Q3 2020 • Fully integrated U.S. commercial team now selling Anika’s expanded product portfolio; currently 30+ sales professionals and over 150 distributors in the U.S • Completed launch activities for seven joi
Slide 5: Enhanced Team
ENHANCED TEAM Management Board of Directors Mike Levitz Jack Henneman Executive Vice President Anika Board of Directors Chief Financial Officer and Treasurer Former Executive, Integra Life Sciences and Former SVP and CFO, Insulet Corporation NewLink Genetics Ben Joseph Steve Richard Vice President A
Slide 6: New Product Development Roadmap
NEW PRODUCT DEVELOPMENT ROADMAP >$8B Global Market Opportunity(1) OA Pain Regenerative Bone Preserving Joint Soft Tissue Repair Management Solutions Technologies ● CINGAL® (US) ● HYALOFAST® (US) ● Resorbable fixation ● Shoulder ● Tactoset ®/Bone ● Anatomy-centric ● Hand and wrist platform ● Products
Slide 7: Q3 2020 Financial Highlights
Q3 2020 FINANCIAL HIGHLIGHTS Dollars in millions Total Revenue Product Line Revenue $29.7 $31.7 37% $124.8 million 7% 93% Cash & Investments as of 58% Sept. 30, 2020 Q3 2019 Q3 2020 Q3 2019 Q3 2020 Joint Pain Management Joint Preservation/Restoration Other • Total revenue increased 7% and product li
Slide 8: 2020 Catalysts Support Long Term Success
2020 CATALYSTS SUPPORT LONG TERM SUCCESS • Recovering procedure volumes toward pre-COVID pro-forma levels, although uneven as COVID hot spots remain a reality into 2021, and uneven impact by product category • Continued successful integration of acquisitions have formed an enhanced organization with
Slide 9: Anika. Restore Active Living.
Anika. Restore Active Living.™ Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with physicians to understand what they need most to treat their patients and we develop